Abstract | BACKGROUND: METHODS: We performed a five-year, randomized, double-blind, placebo-controlled trial statewide, in California, of BIG-IV in 122 infants with suspected (and subsequently laboratory-confirmed) infant botulism (75 caused by type A Clostridium botulinum toxin, and 47 by type B toxin); treatment was given within three days after hospital admission. We subsequently performed a 6-year nationwide, open-label study of 382 laboratory-confirmed cases of infant botulism treated within 18 days after hospital admission. RESULTS: As compared with the control group in the randomized trial, infants treated with BIG-IV had a reduction in the mean length of the hospital stay, the primary efficacy outcome measure, from 5.7 weeks to 2.6 weeks (P<0.001). BIG-IV treatment also reduced the mean duration of intensive care by 3.2 weeks (P<0.001), the mean duration of mechanical ventilation by 2.6 weeks (P=0.01), the mean duration of tube or intravenous feeding by 6.4 weeks (P<0.001), and the mean hospital charges per patient by 88,600 dollars (in 2004 U.S. dollars; P<0.001). There were no serious adverse events attributable to BIG-IV. In the open-label study, infants treated with BIG-IV within seven days of admission had a mean length of hospital stay of 2.2 weeks, and early treatment with BIG-IV shortened the mean length of stay significantly more than did later treatment. CONCLUSIONS: Prompt treatment of infant botulism type A or type B with BIG-IV was safe and effective in shortening the length and cost of the hospital stay and the severity of illness.
|
Authors | Stephen S Arnon, Robert Schechter, Susan E Maslanka, Nicholas P Jewell, Charles L Hatheway |
Journal | The New England journal of medicine
(N Engl J Med)
Vol. 354
Issue 5
Pg. 462-71
(Feb 02 2006)
ISSN: 1533-4406 [Electronic] United States |
PMID | 16452558
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Copyright | Copyright 2006 Massachusetts Medical Society. |
Chemical References |
- Immunoglobulins
- Immunoglobulins, Intravenous
- botulism immune globulin
- rimabotulinumtoxinB
- Botulinum Toxins
- Botulinum Toxins, Type A
|
Topics |
- Botulinum Toxins
(immunology)
- Botulinum Toxins, Type A
(immunology)
- Botulism
(drug therapy)
- Double-Blind Method
- Female
- Follow-Up Studies
- Humans
- Immunoglobulins
(adverse effects, therapeutic use)
- Immunoglobulins, Intravenous
(adverse effects, therapeutic use)
- Infant
- Infant, Newborn
- Length of Stay
- Male
- Treatment Outcome
|